SETD2 and cancer: SETD2 mutations and KDM4A overexpression are together observed in more than 10% of cancers in kidney, large intestines, endometrium, and ovary (Berry and Janknecht, 2013, Dalgliesh et al., 2010, Gerlinger et al., 2012).